GlassScriptPhysician profile
Timberlyn M Beal
NPI 1932551850
$4,350.64
in general payments reported to CMS, 2019-2025
12 companies · $792 in 2025
The $792 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $997 · 2022: $986 · 2023: $818 · 2024: $758 · 2025: $792.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,367.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,367.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,611.88 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $994.14 | 2021-2025 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $488.42 | 2021-2025 | |
| Abbvie INC. | $463.88 | 2021-2024 | |
| Glaxosmithkline, LLC. | $270.02 | 2023-2024 | Arexvy, Trelegy Ellipta |
| Abbott Laboratories | $227.81 | 2022-2025 | Freestyle Libre 3, Cardiomems |
| Biohaven Pharmaceuticals, INC. | $125.00 | 2021 | |
| Redhill Biopharma INC. | $91.48 | 2021 | |
| Insulet Corporation | $24.36 | 2025 | Omnipod |
| Xeris Pharmaceuticals, INC. | $23.26 | 2025 | Gvoke Hypopen |
| Lilly USA, LLC | $16.47 | 2025 | Zepbound, Mounjaro |
| Dexcom, INC. | $13.92 | 2025 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timberlyn Beal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.